Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Syros Pharmaceuticals Price Performance
SYRS Stock opened at $0.98 on Tuesday. The firm has a 50 day moving average of $0.92 and a 200 day moving average of $1.10. The company has a current ratio of 4.22, a quick ratio of 4.22 and a debt-to-equity ratio of 0.62. Syros Pharmaceuticals has a 52 week low of $0.65 and a 52 week high of $5.64.
Syros Pharmaceuticals (NASDAQ:SYRS - Get Rating) last released its earnings results on Monday, May 16th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.08. The company had revenue of $5.47 million during the quarter, compared to analysts' expectations of $4.56 million. Syros Pharmaceuticals had a negative net margin of 403.99% and a negative return on equity of 104.21%. During the same period last year, the business earned ($0.23) EPS. Equities analysts predict that Syros Pharmaceuticals will post -1.26 EPS for the current fiscal year.
Analysts Set New Price Targets
SYRS has been the topic of a number of analyst reports. HC Wainwright cut their price objective on shares of Syros Pharmaceuticals from $10.00 to $6.00 and set a "buy" rating on the stock in a research report on Tuesday, July 12th. StockNews.com raised shares of Syros Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, August 4th. Finally, Alliance Global Partners cut their price objective on shares of Syros Pharmaceuticals to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 16th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $13.80.